nach oben

Tumor Biology

Erschienen in:

01.05.2014 | Research Article

Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group

verfasst von: Kui Zhang, Bin Zhou, Peng Zhang, Zhu Zhang, Peng Chen, Yan Pu, Yaping Song, Lin Zhang

Erschienen in: Tumor Biology | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Nicotinamide phosphoribosyltransferase (Nampt) was served as a useful biomarker for tumorigenesis and for the prediction of cancer survival. In the present study, we analyzed the SNPs of the NAMPT gene and their impact on the susceptibility and prognosis for patients with bladder cancer (BC). The rs61330082, rs2505568 and rs9034 were selected and genotyped by polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) method in 407 patients with bladder cancer and 316 ethnicity-matched healthy control subjects. The genotyping method was confirmed by the DNA sequencing analysis. Statistically significant increased bladder cancer risk was found to be associated with the C allele and CC genotype of rs61330082; nevertheless, decreased bladder cancer risk was revealed to be associated with A allele and AT genotype of rs2505568. Stratified analyses revealed the rs61330082 to be statistically associated with increased bladder cancer risk in smokers and increased invasiveness of bladder cancer. The AT heterozygote of rs2505568 may prevent the recurrence of bladder cancer. Kaplan-Meier curves revealed a statistically significant association of rs2505568 with recurrence-free survival for total bladder cancer patients and non-muscle-invasive bladder cancer patients, and a statistically significant association of rs9034 with recurrence-free survival for muscle-invasive bladder cancer patients. Multiple Cox regression analysis identified the rs2505568 as a possible independent prognostic factor for recurrence-free survival in total bladder cancer patients. Our results suggested an important role for NAMPT in the pathogenesis of bladder cancer and SNPs of NAMPT gene might be a novel genetic biomarker for the prognosis of bladder cancer.

Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.CrossRefPubMedPubMedCentral

Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300.CrossRefPubMed

IARC. Cancer incidence in five continents. IARC scientific publications, vol. 9. Lyon: IARC; 2008. p. 1–837.

DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63:151–66.CrossRefPubMed

Soloway MS, Sofer M, Vaidya A. Contemporary management of stage t1 transitional cell carcinoma of the bladder. J Urol. 2002;167:1573–83.CrossRefPubMed

Saad A, Hanbury DC, McNicholas TA, Boustead GB, Morgan S, Woodman AC. A study comparing various noninvasive methods of detecting bladder cancer in urine. BJU Int. 2002;89:369–73.CrossRefPubMed

Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168:1964–70.CrossRefPubMed

Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994;14:1431–7.CrossRefPubMedPubMedCentral

Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426–30.CrossRefPubMed

10.

Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. J Biol Chem. 2004;279:50754–63.CrossRefPubMed

11.

Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, et al. Functional interaction between parp-1 and parp-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003;22:2255–63.CrossRefPubMedPubMedCentral

12.

Corda D, Di Girolamo M. Functional aspects of protein mono-ADP-ribosylation. EMBO J. 2003;22:1953–8.CrossRefPubMedPubMedCentral

13.

Lee HC. Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers. Ann Rev Pharmacol Toxicol. 2001;41:317–45.CrossRef

14.

Lin SJ, Guarente L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr Opin Cell Biol. 2003;15:241–6.CrossRefPubMed

15.

Hufton SE, Moerkerk PT, Brandwijk R, de Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett. 1999;463:77–82.CrossRefPubMed

16.

Van Beijnum JR, Moerkerk PT, Gerbers AJ, De Bruine AP, Arends JW, Hoogenboom HR, et al. Target validation for genomics using peptide-specific phage antibodies: a study of five gene products overexpressed in colorectal cancer. Int J Cancer J Int Cancer. 2002;101:118–27.CrossRef

17.

Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S, et al. Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci. 2010;101:1286–91.CrossRefPubMed

18.

Srivastava M, Khurana P, Sugadev R. Lung cancer signature biomarkers: tissue specific semantic similarity based clustering of digital differential display (DDD) data. BMC Res Notes. 2012;5:617.CrossRefPubMedPubMedCentral

19.

Dalamaga M. Nicotinamide phosphoribosyl-transferase/visfatin: a missing link between overweight/obesity and postmenopausal breast cancer? Potential preventive and therapeutic perspectives and challenges. Med Hypotheses. 2012;79:617–21.CrossRefPubMed

20.

Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. Nampt overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene. 2011;30:907–21.CrossRefPubMed

21.

Bi TQ, Che XM, Liao XH, Zhang DJ, Long HL, Li HJ, et al. Overexpression of Nampt in gastric cancer and chemopotentiating effects of the Nampt inhibitor fk866 in combination with fluorouracil. Oncol Rep. 2011;26:1251–7.PubMed

22.

Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab: TEM. 2009;20:130–8.CrossRefPubMed

23.

YC, Yang YH, Su JH, Chang HL, Hou MF, Yuan SS (2011) High visfatin expression in breast cancer tissue is associated with poor survival. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 20:1892-1901.

24.

Dalamaga M, Archondakis S, Sotiropoulos G, Karmaniolas K, Pelekanos N, Papadavid E, et al. Could serum visfatin be a potential biomarker for postmenopausal breast cancer? Maturitas. 2012;71:301–8.CrossRefPubMed

25.

Tian W, Zhu Y, Wang Y, Teng F, Zhang H, Liu G, et al. Visfatin, a potential biomarker and prognostic factor for endometrial cancer. Gynecol Oncol. 2013;129:505–12.CrossRefPubMed

26.

Kozomara A, Griffiths-Jones S. miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res. 2011;39:D152–7.CrossRefPubMed

27.

Ke X, Collins A, Ye S. PIRA PCR designer for restriction analysis of single nucleotide polymorphisms. Bioinformatics. 2001;17:838–9.CrossRefPubMed

28.

Sole X, Guino E, Valls J, Iniesta R, Moreno V. SNPStats: a web tool for the analysis of association studies. Bioinformatics. 2006;22:1928–9.CrossRefPubMed

29.

Bi TQ, Che XM. Nampt/PBEF/visfatin and cancer. Cancer Biol Ther. 2010;10:119–25.CrossRefPubMed

30.

Friebe D, Neef M, Kratzsch J, Erbs S, Dittrich K, Garten A, et al. Leucocytes are a major source of circulating nicotinamide phosphoribosyltransferase (Nampt)/pre-b cell colony (PBEF)/visfatin linking obesity and inflammation in humans. Diabetologia. 2011;54:1200–11.CrossRefPubMedPubMedCentral

31.

Bao J, Sack MN. Protein deacetylation by sirtuins: delineating a post-translational regulatory program responsive to nutrient and redox stressors. Cell Mol Life Sci. 2010;67:3073–87.CrossRefPubMedPubMedCentral

32.

Chalkiadaki A, Guarente L. Sirtuins mediate mammalian metabolic responses to nutrient availability. Nat Rev Endocrinol. 2012;8:287–96.CrossRefPubMed

33.

Kim SR, Bae SK, Choi KS, Park SY, Jun HO, Lee JY, et al. Visfatin promotes angiogenesis by activation of extracellular signal-regulated kinase 1/2. Biochem Biophys Res Commun. 2007;357:150–6.CrossRefPubMed

34.

Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356–65.CrossRefPubMed

35.

Hasmann M, Schemainda I. Fk866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 2003;63:7436–42.PubMed

36.

O’Mahony DS, Glavan BJ, Holden TD, Fong C, Black RA, Rona G, et al. Inflammation and immune-related candidate gene associations with acute lung injury susceptibility and severity: a validation study. PLoS ONE. 2012;7:e51104.CrossRefPubMedPubMedCentral

37.

Leander K, Gigante B, Silveira A, Vikstrom M, Hamsten A, Hogberg J. Nampt (visfatin) and Akt1 genetic variants associate with myocardial infarction. Clin Chim Acta Int J Clin Chem. 2012;413:727–32.CrossRef

38.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62:220–41.CrossRefPubMed

39.

American Cancer Society (2009) Smoking and cancer mortality table. http://www.Cancer.Org/docroot/ped/content/ped102x_smoking_and_cancer_mortality_table.Asp. Updated September 18, 2009. Accessed 20 Jan 2010

40.

Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control. 1997;8:346–55.CrossRefPubMed

41.

Brennan P, Bogillot O, Cordier S, Greiser E, Schill W, Vineis P, et al. Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies. Int J Cancer J Int Cancer. 2000;86:289–94.CrossRef

Titel: Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group
verfasst von: Kui Zhang
Bin Zhou
Peng Zhang
Zhu Zhang
Peng Chen
Yan Pu
Yaping Song
Lin Zhang
Publikationsdatum: 01.05.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 5/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1527-z

Springer Medizin

Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2014

The co-expression of telomerase and ALT pathway in human breast cancer tissues

MicroRNA-21 is a novel promising target in cancer radiation therapy

Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation

Association of XRCC1 polymorphisms with thyroid cancer risk

Promoter methylation-mediated downregulation of PRDM5 contributes to the development of lung squamous cell carcinoma

VEGF +405G/C (rs2010963) polymorphisms and digestive system cancer risk: a meta-analysis

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie